Change of CEO at Medivir
September 10, 2002 03:26 ET
|
Medivir
HUDDINGE, Sweden, Sept. 10, 2002 (PRIMEZONE) -- Jonas Frick, CEO of Medivir since Stock Exchange listing in 1996, will leave the Company for a role as a Senior Partner of Scandinavian Life Science...
Medivir Interim Report, 1 Jan.-30 June 2002
July 08, 2002 03:18 ET
|
Medivir
HUDDINGE, Sweden, July 8, 2002 (PRIMEZONE) -- Medivir:
-- MIV-310 demonstrated powerful antiviral effect on patients with
multiresistant HIV; these results, from a phase IIa trial, were
...
Results on MIV-310 in phase IIa study
May 31, 2002 02:12 ET
|
Medivir
HUDDINGE, Sweden, May 31, 2002 (PRIMEZONE) -- A phase IIa clinical study with Medivir's compound MIV-310 shows a major antiviral effect in patients with multi drug resistant HIV.
The addition of...
Medivir: Proof of Principle in Research on Treatment of Multiple Sclerosis
May 29, 2002 04:14 ET
|
Medivir
HUDDINGE, Sweden, May 29, 2002 (PRIMEZONE) -- Medivir and Peptimmune jointly announced today that, an orally active, small molecule inhibitor of the protease enzyme Cathepsin S, suppresses the...
Medivir: Interim Report, 1 January - 31 March 2002 (with link)
April 26, 2002 05:33 ET
|
Medivir
HUDDINGE, Sweden, April 26, 2002 (PRIMEZONE) -- Medivir:
- MIV-606 against shingles: US market rights outlicensed to Reliant
Pharmaceuticals, raising a SEK 50 m up-front payment. Medivir...
Change in the Medivir HIV program
April 25, 2002 00:39 ET
|
Medivir
HUDDINGE, Sweden, April 25, 2002 (PRIMEZONE) -- During its Q1 report telephone conference on April 24th Chiron announced that it has decided to stop the collaboration with Medivir on MIV-150...
Medivir Signs Agreement to Out-License Its Novel HIV/AIDS Treatment to Roche; New Promising Drug Added to Roche's Strong HIV Portfolio
April 15, 2002 08:30 ET
|
Medivir
HUDDINGE, Sweden, April 15, 2002 (PRIMEZONE) -- Medivir today announced that it has signed an agreement with Roche for the out-licensing of its innovative HIV treatment MV026048. MV026048 is a...
Medivir: Financial Statement, 1 January - 31 December 2001 (with link)
February 15, 2002 08:15 ET
|
Medivir
HUDDINGE, Sweden, Feb. 15, 2002 (PRIMEZONE) -- Medivir:
-- MIV-606 against shingles: Outlicensing activities are in an
intensive phase.
-- In December, Medivir and Peptimmune announced a...